211 related articles for article (PubMed ID: 34102189)
1. Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome.
Li Y; Kang L; Rong K; Zhang Y; Suo Y; Yuan M; Bao Q; Shao S; Tse G; Li R; Liu T; Li G
Life Sci; 2021 Sep; 280():119692. PubMed ID: 34102189
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor Neprilysin inhibitor (LCZ696) compared to Valsartan attenuates Hepatotoxicity in STZ-induced hyperglycemic rats.
Alqahtani F; Mohany M; Alasmari AF; Alanazi AZ; Belali OM; Ahmed MM; Al-Rejaie SS
Int J Med Sci; 2020; 17(18):3098-3106. PubMed ID: 33173431
[No Abstract] [Full Text] [Related]
3. Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury.
Lee S; Hwang HS; Song N; Kang GH; Choi KH; Ji E; Song JM; Kang DH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445301
[TBL] [Abstract][Full Text] [Related]
4. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
[TBL] [Abstract][Full Text] [Related]
5. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Voors AA; Gori M; Liu LC; Claggett B; Zile MR; Pieske B; McMurray JJ; Packer M; Shi V; Lefkowitz MP; Solomon SD;
Eur J Heart Fail; 2015 May; 17(5):510-7. PubMed ID: 25657064
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.
Miura SI; Suematsu Y; Matsuo Y; Tomita S; Nakayama A; Goto M; Arimura T; Kuwano T; Yahiro E; Saku K
Hypertens Res; 2016 Nov; 39(11):758-763. PubMed ID: 27334058
[TBL] [Abstract][Full Text] [Related]
7. Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats.
Miyoshi T; Nakamura K; Miura D; Yoshida M; Saito Y; Akagi S; Ohno Y; Kondo M; Ito H
Cardiol J; 2019; 26(5):575-583. PubMed ID: 29718530
[TBL] [Abstract][Full Text] [Related]
8. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
9. The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats.
Rahman A; Sherajee SJ; Rafiq K; Kobara H; Masaki T; Nakano D; Morikawa T; Konishi Y; Imanishi M; Nishiyama A
J Pharmacol Sci; 2020 Mar; 142(3):124-126. PubMed ID: 31924408
[TBL] [Abstract][Full Text] [Related]
10. Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Liu Y; Fan Y; Li J; Chen M; Chen A; Yang D; Guan X; Cao Y
Biomed Pharmacother; 2021 Jan; 133():110824. PubMed ID: 33378988
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
Zhang Y; Yuan M; Suo Y; Yang Q; Shao S; Li Y; Wang Y; Bao Q; Liu T; Li G
Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):848-857. PubMed ID: 35596518
[TBL] [Abstract][Full Text] [Related]
12. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
Suematsu Y; Miura S; Goto M; Matsuo Y; Arimura T; Kuwano T; Imaizumi S; Iwata A; Yahiro E; Saku K
Eur J Heart Fail; 2016 Apr; 18(4):386-93. PubMed ID: 26749570
[TBL] [Abstract][Full Text] [Related]
13. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
[TBL] [Abstract][Full Text] [Related]
15. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
16. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.
von Lueder TG; Wang BH; Kompa AR; Huang L; Webb R; Jordaan P; Atar D; Krum H
Circ Heart Fail; 2015 Jan; 8(1):71-8. PubMed ID: 25362207
[TBL] [Abstract][Full Text] [Related]
18. LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease.
Suematsu Y; Jing W; Nunes A; Kashyap ML; Khazaeli M; Vaziri ND; Moradi H
J Card Fail; 2018 Apr; 24(4):266-275. PubMed ID: 29325796
[TBL] [Abstract][Full Text] [Related]
19. The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model.
Chiu HW; Wu CH; Lin WY; Wong WT; Tsai WC; Hsu HT; Ho CL; Cheng SM; Cheng CC; Yang SP; Li LH; Hua KF
Inflammation; 2024 Apr; 47(2):696-717. PubMed ID: 38319541
[TBL] [Abstract][Full Text] [Related]
20. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]